Therapeutic versus Prophylactic Anticoagulation with Low Molecular Weight Heparin for Moderate COVID-19 Patients
Last updated: 01 Jan 2025
10.21608/zumj.2024.279878.3290
anticoagulation, Coagulopathy, Heparin, mortality, Thrombosis
Wafiya
Mahdy
Ramadan
Department of Anesthesiology, Intensive care and Pain management, Faculty of Medicine, Menoufia University, Egypt
wafia.mahdi@med.menofia.edu.eg
Aya
Mohammed
Abdelghany
Department of Anesthesiology, Intensive care and Pain management, Faculty of Medicine, Menoufia University, Egypt
doctoraya991702@gmail.com
Abdel Rahman
Ahmed
Ahmed
Department of Anesthesiology, Intensive care and Pain management, Faculty of Medicine, Menoufia University, Egypt
rahman80eg@yahoo.com
Nadia
Bahgat
Mohee ELdin
Department of Anesthesiology, Intensive care and Pain management, Faculty of Medicine, Menoufia University, Egypt
dr_nmbahgat@med.menofia.edu.eg
30
9
51783
2024-12-01
2024-03-27
2024-12-01
4,687
4,697
1110-1431
2357-0717
https://zumj.journals.ekb.eg/article_349710.html
https://zumj.journals.ekb.eg/service?article_code=349710
41
Original Article
273
Journal
Zagazig University Medical Journal
https://zumj.journals.ekb.eg/
Therapeutic versus Prophylactic Anticoagulation with Low Molecular Weight Heparin for Moderate COVID-19 Patients
Details
Type
Article
Created At
30 Dec 2024